NOTES_NNS TO_TO THE_DT CONSOLIDATED_JJ FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 2_CD ._.
Acquisitions_NNS of_IN subsidiaries_NNS i_FW Acquisition_NNP of_IN Urology_NNP Solutions_NNPS Pty_NNP Limited_NNP On_IN 16_CD March_NNP 2005_CD ,_, the_DT Group_NNP acquired_VBD 100_CD %_NN of_IN the_DT equity_NN of_IN Urology_NNP Solutions_NNPS Pty_NNP Limited_NNP renamed_VBD Gyrus_NNP Australasia_NNP Pty_NNP Limited_NNP ,_, the_DT exclusive_JJ distributor_NN of_IN Gyruss_NNP surgical_JJ products_NNS in_IN Australia_NNP and_CC New_NNP Zealand_NNP for_IN total_JJ consideration_NN of_IN 1,170,000_CD satisfied_VBN by_IN cash_NN and_CC deferred_VBN consideration_NN ._.
In_IN the_DT nine_CD months_NNS to_TO 31_CD December_NNP 2005_CD the_DT subsidiary_NN reduced_VBN Group_NNP operating_NN profit_NN by_IN 421,000_CD ._.
If_IN the_DT acquisition_NN had_VBD occurred_VBN on_IN 1_CD January_NNP 2005_CD ,_, the_DT subsidiary_NN would_MD have_VB reduced_VBN Group_NNP operating_NN profit_NN by_IN 460,000_CD ._.
Effect_NN of_IN acquisition_NN The_DT acquisition_NN had_VBD the_DT following_JJ effect_NN on_IN the_DT Groups_NNS assets_NNS and_CC liabilities_NNS ._.
Acquirees_NNP book_NN values_VBZ Fair_NNP value_NN adjustments_NNS Acquisition_NNP amounts_VBZ Acquirees_NNP net_JJ assets_NNS at_IN the_DT acquisition_NN date_NN 000 000 000_CD Property_NN ,_, plant_NN and_CC equipment_NN 34_CD 34_CD Intangible_JJ assets_NNS 387_CD 387_CD Inventories_NNS 318_CD 19_CD 337_CD Trade_NNP and_CC other_JJ receivables_NN 125_CD 125_CD Cash_NN and_CC cash_NN equivalents_NNS 32_CD 32_CD Trade_NNP and_CC other_JJ payables_NNS 351 139 490_CD Net_JJ identifiable_JJ assets_NNS and_CC liabilities_NNS 158 267 425_CD Goodwill_NNP on_IN acquisition_NN 745_CD Total_JJ consideration_NN 1,170_CD Satisfied_VBN by_IN :_: Cash_NN 797_CD Deferred_JJ consideration_NN 373_CD Total_JJ consideration_NN 1,170_CD Cash_NN consideration_NN 797_CD Less_RBR :_: cash_NN acquired_VBN on_IN acquisition_NN 32_CD Net_JJ cash_NN out_RP flow_NN arising_VBG on_IN acquisition_NN 765_CD This_DT acquisition_NN provides_VBZ Gyrus_NNP with_IN the_DT opportunity_NN to_TO sell_VB its_PRP$ range_NN of_IN ENT_NNP products_NNS through_IN this_DT distribution_NN channel_NN ._.
Goodwill_NN of_IN 745,000_CD has_VBZ arisen_VBN on_IN this_DT transaction_NN as_IN a_DT result_NN of_IN the_DT potential_NN for_IN generating_VBG additional_JJ sales_NNS ._.
On_IN 12_CD May_NNP 2005_CD ,_, Gyrus_NNP Australasia_NNP Pty_NNP Ltd_NNP took_VBD over_RP the_DT distribution_NN of_IN ENT_NNP products_NNS in_IN Australia_NNP from_IN Global_NNP Scientific_NNP Pty_NNP Ltd_NNP and_CC purchased_VBD business_NN records_NNS and_CC inventory_NN for_IN cash_NN consideration_NN of_IN 511,000_CD ._.
Acquirees_NNP book_NN values_VBZ Fair_NNP value_NN adjustments_NNS Acquisition_NNP amounts_VBZ 000 000 000_CD Intangible_JJ assets_NNS 161_CD 161_CD Inventories_NNS 346 103 243_CD Net_JJ identifiable_JJ assets_NNS and_CC liabilities_NNS 346_CD 58_CD 404_CD Goodwill_NNP on_IN acquisition_NN 107_CD Total_JJ consideration_NN satisfied_VBN by_IN cash_NN 511_CD The_DT acquisition_NN of_IN business_NN records_NNS and_CC inventory_NN from_IN Global_JJ Scientific_NNP Pty_NNP Ltd_NNP provides_VBZ Gyrus_NNP with_IN a_DT further_JJ opportunity_NN to_TO sell_VB its_PRP$ range_NN of_IN ENT_NNP products_NNS through_IN established_VBN distribution_NN channels_NNS ._.
Goodwill_NN of_IN 107,000_CD has_VBZ arisen_VBN on_IN this_DT transaction_NN as_IN a_DT result_NN of_IN the_DT potential_NN for_IN generating_VBG additional_JJ sales_NNS ._.
Gyrus_NNP Group_NNP PLC_NNP Annual_JJ Report_NNP and_CC Accounts_NNPS 2005_CD 56_CD ii_NNP Acquisition_NNP of_IN American_NNP Cystoscope_NNP Makers_NNPS Inc_NNP On_IN 21_CD July_NNP 2005_CD ,_, Gyrus_NNP Group_NNP PLC_NNP acquired_VBD 100_CD %_NN of_IN the_DT share_NN capital_NN of_IN American_JJ Cystoscope_NNP Makers_NNPS Inc_NNP ACMI_NNP ._.
ACMI_NNP designs_NNS ,_, manufactures_VBZ ,_, markets_NNS and_CC services_NNS surgical_JJ visualisation_NN and_CC treatment_NN systems_NNS used_VBN by_IN surgeons_NNS and_CC physicians_NNS primarily_RB for_IN diagnosis_NN and_CC minimally_RB invasive_JJ surgery_NN in_IN the_DT field_NN of_IN Urology_NNP and_CC Gynaecology_NNP ._.
ACMI_NNP was_VBD acquired_VBN for_IN a_DT consideration_NN of_IN US$_$ 332_CD million_CD plus_IN the_DT assumption_NN of_IN debt_NN and_CC other_JJ obligations_NNS subsequently_RB repaid_VBN by_IN the_DT Company_NN of_IN US$_$ 168_CD million_CD less_JJR the_DT assumption_NN of_IN cash_NN balances_NNS on_IN the_DT date_NN of_IN acquisition_NN ._.
The_DT consideration_NN was_VBD satisfied_VBN by_IN the_DT issue_NN of_IN 61,560,025_CD placing_VBG shares_NNS at_IN 250p_JJ per_IN placing_VBG share_NN and_CC new_JJ banking_NN facilities_NNS ._.
The_DT entire_JJ proceeds_NNS of_IN the_DT allotment_NN of_IN the_DT placing_VBG shares_NNS which_WDT were_VBD issued_VBN in_IN consideration_NN for_IN the_DT outstanding_JJ common_JJ stock_NN of_IN ACMI_NNP were_VBD paid_VBN to_TO the_DT Sellers_NNS ._.
New_JJ banking_NN facilities_NNS of_IN US$_$ 280_CD million_CD include_VBP a_DT five_CD year_NN fixed_VBN term_NN loan_NN of_IN US$_$ 250_CD million_CD and_CC a_DT US$_$ 30_CD million_CD revolving_JJ credit_NN facility_NN secured_VBN by_IN a_DT fixed_VBN and_CC floating_VBG charge_NN over_IN the_DT assets_NNS of_IN the_DT Group_NNP see_VB note_NN 18_CD ._.
Acquirees_NNP book_NN values_VBZ Fair_NNP value_NN adjustments_NNS Acquisition_NNP amounts_VBZ 000 000 000_CD Property_NN ,_, plant_NN and_CC equipment_NN 10,440_CD 1,991_CD 8,449_CD Intangible_JJ assets_NNS 612_CD 108,812_CD 109,424_CD Inventories_NNS 15,938_CD 4,686_CD 20,624_CD Trade_NNP and_CC other_JJ receivables_NN 16,442_CD 16,442_CD Deferred_JJ tax_NN asset_NN liability_NN 216_CD 27,009_CD 26,793_CD Cash_NN and_CC cash_NN equivalents_NNS 2,642_CD 2,642_CD Trade_NNP and_CC other_JJ payables_NNS 30,243_CD 30,243_CD Provisions_NNS 2,245_CD 2,245_CD Bank_NNP loan_NN 83,365_CD 83,365_CD Net_JJ identifiable_JJ assets_NNS and_CC liabilities_NNS 69,563_CD 84,498_CD 14,935_CD Goodwill_NNP on_IN acquisition_NN 180,351_CD Total_JJ consideration_NN including_VBG costs_NNS 195,286_CD Purchase_NN price_NN of_IN $_$ 332,460,951_CD 186,368_CD Acquisition_NNP costs_NNS taken_VBN to_TO cost_NN of_IN investment_NN 6,938_CD Funds_NNS from_IN exercise_NN of_IN option_NN 1,980_CD Total_JJ consideration_NN 195,286_CD In_IN order_NN to_TO ensure_VB that_IN 116_CD million_CD of_IN placing_VBG proceeds_NNS raised_VBN would_MD translate_VB into_IN the_DT minimum_NN US$_$ amount_NN required_VBN for_IN the_DT completion_NN of_IN the_DT acquisition_NN ,_, Gyrus_NNP Group_NNP PLC_NNP entered_VBD into_IN an_DT option_NN agreement_NN on_IN the_DT announcement_NN date_NN ._.
The_DT net_JJ funds_NNS received_VBN from_IN the_DT sale_NN of_IN this_DT option_NN ,_, approximately_RB one_CD month_NN later_RB ,_, were_VBD 1,980,000_CD ._.
Satisfied_VBN by_IN US$_$ 000_CD 000_CD Share_NN placing_VBG 153,901_CD Cash_NN 32,467_CD Purchase_NN price_NN 332,461_CD 186,368_CD Cash_NN acquired_VBN 4,712_CD 2,642_CD ACMI_NNP debt_NN paid_VBN on_IN acquisition_NN 167,763_CD 94,052_CD Acquisition_NNP costs_NNS 10,721_CD Net_JJ cash_NN outflow_NN as_IN a_DT result_NN of_IN the_DT acquisition_NN 495,512_CD 288,499_CD Includes_VBZ 6,938,000_CD of_IN acquisition_NN costs_NNS taken_VBN to_TO cost_NN of_IN investment_NN and_CC 3,783,000_CD of_IN acquisition_NN costs_NNS relating_VBG to_TO the_DT share_NN placing_VBG that_IN were_VBD taken_VBN to_TO the_DT share_NN premium_NN account_NN ._.
Fair_NNP value_NN adjustments_NNS A_DT valuation_NN was_VBD commissioned_VBN to_TO identify_VB and_CC value_VB intangible_JJ assets_NNS ._.
As_IN a_DT result_NN of_IN the_DT valuation_NN ,_, 108,812,000_CD of_IN intangible_JJ assets_NNS were_VBD recognized_VBN which_WDT can_MD be_VB analyzed_VBN as_IN follows_VBZ :_: 000_CD Developed_VBN product_NN technology_NN Urology_NNP 12,557_CD Developed_VBN product_NN technology_NN Gynaecology_NNP 4,148_CD In_IN process_NN R&D_NNP Urology_NNP 9,362_CD In_IN process_NN R&D_NNP Gynaecology_NNP 2,915_CD Trademark_NNP tradename_NN portfolio_NN Urology_NNP 28,141_CD Trademark_NNP tradename_NN portfolio_NN Gynaecology_NNP 5,662_CD Customer_NN relationships_NNS 46,471_CD Less_RBR :_: amounts_NNS included_VBD in_IN opening_VBG balance_NN sheet_NN in_IN connection_NN with_IN the_DT above_JJ 444_CD Total_JJ 108,812_CD A_DT valuation_NN study_NN was_VBD commissioned_VBN on_IN the_DT land_NN and_CC buildings_NNS owned_VBN by_IN ACMI_NNP ._.
As_IN a_DT result_NN of_IN the_DT valuation_NN the_DT value_NN attributed_VBD to_TO property_NN ,_, plant_NN and_CC equipment_NN was_VBD reduced_VBN by_IN 1,991,000_CD ._.
Gyrus_NNP Group_NNP PLC_NNP Annual_JJ Report_NNP and_CC Accounts_NNPS 2005_CD 57_CD
